Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications, markets has the jitters and the sector has the heebie-jeebies

August 18, 2017 7:35am

Where is the sustainable value in cell therapy land again?

Share pricing leadership has its issues … it slips, dips and uncertainty keeps it uncontrollable

Preview RMi's morning call. To get the pre-open briefing, plus daily access of the happenings and realities of “our” universe - SUBSCRIBE!

Critical indication ahead of “our” universe’s open!

Flat to lower open expected

Dow futures are DOWN -0.08% and NASDAQ futures are UP +0.22%

U.S. stock index futures pointed to a flat open on Friday, as investors took note of the negative trading sentiment seen globally in light of the terror attack in Barcelona on Thursday.

European stocks were sharply lower as investors reacted to Spain's worst terror attack in more than 13 years.

Asia markets were pressured after investors on Wall Street sold off on growing uncertainty over the Trump administration's ability to follow through on its economic policies.

Data docket: consumer sentiment data is set to come out at 10 a.m. ET.

Political issues that affect the trading day: turbulence surrounding President Donald trump's leadership, economic policies and his recent statements on the white supremacist rally in Virginia, continue to weigh on sentiment.

The cell therapy sector closed NEGATIVE on Thursday, NEUTRAL on Wednesday, and NEGATIVE on Tuesday, POSITIVE on Monday and last Friday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

· Thursday closed NEGATIVE with 30 decliners, 9 advancers and 4 flats;

· Wednesday closed NEUTRAL with 21 decliners, 21 advancers and 1 flat;

· Tuesday closed NEGATIVE with 24 decliners, 15 advancers and 4 flats;

· Monday closed POSITIVE with 12 decliners, 28 advancers and 3 flats;

· Last Friday closed POSITIVE with 14 decliners, 28 advancers and 1 flat;

Henry ’omics:

As I had stated the evening post, “…sector stumbles; volatility jumps 32.45% as many trade the overbought to being oversold. It’s portrayed to be a platform to play shuffle the stocks and make the short-side buck. As investors get consistently wiped clean.”

This may be the most drugged-up sector as the same old patterns keep repeating themselves!

Even as tensions heightened between the oversold and the overbought, the undervalued become more glaring or are they?

The old issue of climbing that “wall of worry” seeds more and more predictions of a major sell-off.

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

Watch list:

The iShares Nasdaq Biotechnology (IBB) closed down -1.70% on Thursday and is indicating a NEGATIVE -0.01% in Friday’s pre-market;
The SPDR S&P Biotech ETF (XBI) closed Thursday down -1.91% and is NOT indicating in Friday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) closed down -1.25% Thursday and is NOT indicating in Friday’s pre-open;
The iShares Russell 2000 (IWM) closed down -1.80% on Thursday and is indicating a NEGATIVE -0.24% pre-open on Friday

Q2/17 reporting for … to date:

Regenerative Medicine Earnings Scorecard - Q2/2017 - to date … http://www.regmedinvestors.com/articles/9841

Companies in my headlights:

Good day to sit out the scrum and be an observer …

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 25 min ago
RegMed Investors (RMi) Closing Bell: a tough week; tied to cross-currents of geopolitical conflicts and recurring inflation

15 hours 8 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.